Open AccessAssessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
Author(s) -
Tan Rachel H.,
Kril Jillian J.,
Yang Yue,
Tom Nicole,
Hodges John R.,
Villemagne Victor L.,
Rowe Christopher C.,
Leyton Cristian E.,
Kwok John B.J.,
Ittner Lars M.,
Halliday Glenda M.
Publication year - 2017
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2017.05.005
Subject(s) - frontotemporal dementia , dementia , medicine , amyloid (mycology) , pathology , psychology , neuroscience , disease
The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes. Methods Aβ was assessed in 98 autopsy‐confirmed FTD and 36 control cases, and the pathological accuracy of 11 C‐Pittsburgh compound B (PiB)–positron emission tomography imaging was assessed in a subset of FTD cases ( n = 15). Results Aβ was identified in a similar proportion of FTD syndromes and age‐matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Aβ with PiB standard uptake value ratio scaled to the white matter. Discussion The present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.